TY - JOUR
T1 - ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention
AU - Ostrander, Julie H.
AU - Baker, Joseph C.
AU - Lem, Siya
AU - Broadwater, Gloria
AU - Bean, Gregory R.
AU - D'Amato, Nicholas C.
AU - Goldenberg, Vanessa K.
AU - Rowell, Craig
AU - Ibarra-Drendall, Catherine
AU - Grant, Tracey
AU - Pilie, Patrick G.
AU - Vasilatos, Shauna N.
AU - Troch, Michelle M.
AU - Scott, Victoria
AU - Wilke, Lee G.
AU - Paisie, Carolyn
AU - Rabiner, Sarah M.
AU - Torres-Hernandez, Alejandro
AU - Zalles, Carola M.
AU - Seewaldt, Victoria L.
PY - 2008/8
Y1 - 2008/8
N2 - Purpose: Currently, we lack biomarkers to predict whether high-risk women with mammary atypia will respond to tamoxifen chemoprevention. Experimental Design: Thirty-four women with cytologic mammary atypia from the Duke University High-Risk clinic were offered tamoxifen chemoprevention. We tested whether ESR1 promoter hypermethylation and/or estrogen receptor (ER) protein expression by immunohistochemistry predicted persistent atypia in 18 women who were treated with tamoxifen for 12 months and in 16 untreated controls. Results: We observed a statistically significant decrease in the Masood score of women on tamoxifen chemoprevention for 12 months compared with controlwomen. This was a significant interaction effect of time (0, 6, and 12 months) and treatment group (tamoxifen versus control) P = 0.0007. However, neither ESR1 promoter hypermethylation nor low ER expression predicted persistent atypia in Random Periareolar Fine Needle Aspiration after 12 months tamoxifen prevention. Conclusions: Results from this single institution pilot study provide evidence that, unlike for invasive breast cancer, ESR1 promoter hypermethylation and/or low ER expression is not a reliable marker of tamoxifen-resistant atypia.
AB - Purpose: Currently, we lack biomarkers to predict whether high-risk women with mammary atypia will respond to tamoxifen chemoprevention. Experimental Design: Thirty-four women with cytologic mammary atypia from the Duke University High-Risk clinic were offered tamoxifen chemoprevention. We tested whether ESR1 promoter hypermethylation and/or estrogen receptor (ER) protein expression by immunohistochemistry predicted persistent atypia in 18 women who were treated with tamoxifen for 12 months and in 16 untreated controls. Results: We observed a statistically significant decrease in the Masood score of women on tamoxifen chemoprevention for 12 months compared with controlwomen. This was a significant interaction effect of time (0, 6, and 12 months) and treatment group (tamoxifen versus control) P = 0.0007. However, neither ESR1 promoter hypermethylation nor low ER expression predicted persistent atypia in Random Periareolar Fine Needle Aspiration after 12 months tamoxifen prevention. Conclusions: Results from this single institution pilot study provide evidence that, unlike for invasive breast cancer, ESR1 promoter hypermethylation and/or low ER expression is not a reliable marker of tamoxifen-resistant atypia.
UR - http://www.scopus.com/inward/record.url?scp=54049132594&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=54049132594&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-07-2696
DO - 10.1158/1055-9965.EPI-07-2696
M3 - Article
C2 - 18708376
AN - SCOPUS:54049132594
SN - 1055-9965
VL - 17
SP - 1884
EP - 1890
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 8
ER -
